Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.

Top Sections
Coding
Dermpath Diagnosis
For Residents
Photo Challenge
Tips
ct
Main menu
CUTIS Main Menu
Explore menu
CUTIS Explore Menu
Proclivity ID
18823001
Unpublish
Negative Keywords
ammunition
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
Negative Keywords Excluded Elements
div[contains(@class, 'alert ad-blocker')]
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
Altmetric
DSM Affiliated
Display in offset block
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Clinical
Slot System
Featured Buckets
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC
Expire Announcement Bar
Wed, 01/29/2025 - 13:41
Use larger logo size
Off
publication_blueconic_enabled
Off
Show More Destinations Menu
Disable Adhesion on Publication
Off
Restore Menu Label on Mobile Navigation
Disable Facebook Pixel from Publication
Exclude this publication from publication selection on articles and quiz
Gating Strategy
First Page Free
Challenge Center
Disable Inline Native ads
survey writer start date
Wed, 01/29/2025 - 13:41
Current Issue
Title
Cutis
Description

A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.

Current Issue Reference

Space Heater–Induced Bullous Erythema Ab Igne

Article Type
Changed
Thu, 01/10/2019 - 13:44
Display Headline
Space Heater–Induced Bullous Erythema Ab Igne

To the Editor:

Erythema ab igne (EAI) is a reticular erythematous hyperpigmentation of skin repeatedly exposed to moderate heat.1 It usually is asymptomatic, though some patients report itching or burning at the site.2 Historically caused by exposure to coal stoves or open fires, EAI has become increasingly common among individuals using space heaters, heating pads, or laptop computers near bare skin.2,3 Although EAI itself is benign and usually resolves with the removal of the exposure, it remains of clinical importance because of its association with underlying chronic disease, as chronic pain often is managed with frequent heating pad or hot water bottle use.2 Additionally, accurate diagnosis is important given the future risk for malignancy, as chronic changes of EAI have been reported to lead to squamous cell carcinoma or rarely Merkel cell carcinoma.2 Erythema ab igne is not traditionally associated with the formation of bullae; however, we present a case of bullous EAI that we believe highlights the importance of including this condition in the differential diagnosis of bullous disorders.

A 55-year-old man was admitted for presumed cellulitis of the bilateral legs. The patient had developed hyperpigmented discoloration of the medial surface of both legs with subsequent formation of tense bullae over the last 2 months. The dermatology department was consulted, as there was concern for bullous pemphigoid. The patient’s medical history was notable for hypertension, hyperlipidemia, diet-controlled type 2 diabetes mellitus, and hepatitis C virus with cirrhosis. The patient denied pruritus, pain, or known exposure of the legs to potential irritants prior to developing the lesions; however, with additional questioning he did report frequently sitting in front of a space heater with bare legs. Physical examination revealed multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (Figure 1). Many of the bullae were unroofed with full-thickness ulceration. Biopsies were taken for hematoxylin and eosin staining (Figure 2) and direct immunofluorescence.

Figure 1. Bullous erythema ab igne. Bilateral legs (A) with multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (B).

Basic hematologic and metabolic laboratory test results as well as blood cultures were negative. Wound culture was positive for methicillin-resistant Staphylococcus aureus. Histologic examination showed interface dermatitis with subepidermal vesicle (Figure 2). Scattered necrotic keratinocytes were present in the adjacent epidermis, and focal subtle vacuolar alteration of the dermoepidermal junction was seen (Figure 3). Sparse perivascular mononuclear cells and scattered melanophages were present in the dermis. Direct immunofluorescence showed no diagnostic immunopathologic abnormality. Focal weak nonspecific vascular positivity for IgG and C3 was seen, but IgA and IgM were negative. Although not specific, these changes were compatible with EAI in the clinical context provided. The diagnosis of bullous EAI with superimposed staphylococcal infection was made.

Figure 2. Bullous erythema ab igne. Interface dermatitis with subepidermal vesicle (H&E, original magnification ×100).

Figure 3. Bullous erythema ab igne. Scattered necrotic keratinocytesin the adjacent epidermis and focal subtle vacuolar alteration of the dermoepidermal junction (H&E, original magnification ×400).

Although rare, there have been reports of a bullous variant of EAI. Flanagan et al4 described 3 cases of bullous EAI with histopathology similar to our case. All 3 biopsies showed subepidermal separation with a mild perivascular dermal lymphocytic infiltrate. Direct immunofluorescence was negative in 2 cases but showed nonspecific weak patchy deposition of IgM along the dermoepidermal junction.4 Although our case was negative for IgM, there was a similar weak nonspecific distribution of IgG. Kokturk et al5 described a case of bullous EAI in a man with repeated exposure to a space heater. The lesions showed subepidermal separation of the epidermis; increased elastic fibers; dilated dermal capillaries; melanophages in the upper dermis; and a mild, superficial, perivascular-lymphocytic infiltrate. Direct immunofluorescence showed no immune deposits.5 Several earlier cases of bullae associated with EAI have been reported in the literature but were thought to be bullous lichen planus superimposed on EAI.6 Our case, which exhibited similar historical, physical, and histopathologic findings, strengthens the argument for a defined bullous variant of EAI.

References
  1. Baruchin AM. Erythema ab igne—a neglected entity? Burns. 1994;20:460-462.
  2. Arnold AW, Itin PH. Laptop computer−induced erythema ab igne in a child and review of the literature [published online October 4, 2010]. Pediatrics. 2010;126:E1227-E1230.
  3. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162:77-78.
  4. Flanagan N, Watson R, Sweeney E, et al. Bullous erythema ab igne. Br J Dermatol. 1996;134:1159-1160.
  5. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  6. Horio T, Imamura S. Bullous lichen planus developed on erythema ab igne. J Dermatol. 1986;13:203-207.
Article PDF
Author and Disclosure Information

From the University of Tennessee Health Science Center, Memphis. Drs. Redding, Watts, Lee, Kennedy, and Skinner are from the Kaplan-Amonette Department of Dermatology, and Dr. Shimek is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Katherine S. Redding, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Issue
Cutis - 100(2)
Publications
Topics
Page Number
E9-E10
Sections
Author and Disclosure Information

From the University of Tennessee Health Science Center, Memphis. Drs. Redding, Watts, Lee, Kennedy, and Skinner are from the Kaplan-Amonette Department of Dermatology, and Dr. Shimek is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Katherine S. Redding, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Author and Disclosure Information

From the University of Tennessee Health Science Center, Memphis. Drs. Redding, Watts, Lee, Kennedy, and Skinner are from the Kaplan-Amonette Department of Dermatology, and Dr. Shimek is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Katherine S. Redding, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Article PDF
Article PDF
Related Articles

To the Editor:

Erythema ab igne (EAI) is a reticular erythematous hyperpigmentation of skin repeatedly exposed to moderate heat.1 It usually is asymptomatic, though some patients report itching or burning at the site.2 Historically caused by exposure to coal stoves or open fires, EAI has become increasingly common among individuals using space heaters, heating pads, or laptop computers near bare skin.2,3 Although EAI itself is benign and usually resolves with the removal of the exposure, it remains of clinical importance because of its association with underlying chronic disease, as chronic pain often is managed with frequent heating pad or hot water bottle use.2 Additionally, accurate diagnosis is important given the future risk for malignancy, as chronic changes of EAI have been reported to lead to squamous cell carcinoma or rarely Merkel cell carcinoma.2 Erythema ab igne is not traditionally associated with the formation of bullae; however, we present a case of bullous EAI that we believe highlights the importance of including this condition in the differential diagnosis of bullous disorders.

A 55-year-old man was admitted for presumed cellulitis of the bilateral legs. The patient had developed hyperpigmented discoloration of the medial surface of both legs with subsequent formation of tense bullae over the last 2 months. The dermatology department was consulted, as there was concern for bullous pemphigoid. The patient’s medical history was notable for hypertension, hyperlipidemia, diet-controlled type 2 diabetes mellitus, and hepatitis C virus with cirrhosis. The patient denied pruritus, pain, or known exposure of the legs to potential irritants prior to developing the lesions; however, with additional questioning he did report frequently sitting in front of a space heater with bare legs. Physical examination revealed multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (Figure 1). Many of the bullae were unroofed with full-thickness ulceration. Biopsies were taken for hematoxylin and eosin staining (Figure 2) and direct immunofluorescence.

Figure 1. Bullous erythema ab igne. Bilateral legs (A) with multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (B).

Basic hematologic and metabolic laboratory test results as well as blood cultures were negative. Wound culture was positive for methicillin-resistant Staphylococcus aureus. Histologic examination showed interface dermatitis with subepidermal vesicle (Figure 2). Scattered necrotic keratinocytes were present in the adjacent epidermis, and focal subtle vacuolar alteration of the dermoepidermal junction was seen (Figure 3). Sparse perivascular mononuclear cells and scattered melanophages were present in the dermis. Direct immunofluorescence showed no diagnostic immunopathologic abnormality. Focal weak nonspecific vascular positivity for IgG and C3 was seen, but IgA and IgM were negative. Although not specific, these changes were compatible with EAI in the clinical context provided. The diagnosis of bullous EAI with superimposed staphylococcal infection was made.

Figure 2. Bullous erythema ab igne. Interface dermatitis with subepidermal vesicle (H&E, original magnification ×100).

Figure 3. Bullous erythema ab igne. Scattered necrotic keratinocytesin the adjacent epidermis and focal subtle vacuolar alteration of the dermoepidermal junction (H&E, original magnification ×400).

Although rare, there have been reports of a bullous variant of EAI. Flanagan et al4 described 3 cases of bullous EAI with histopathology similar to our case. All 3 biopsies showed subepidermal separation with a mild perivascular dermal lymphocytic infiltrate. Direct immunofluorescence was negative in 2 cases but showed nonspecific weak patchy deposition of IgM along the dermoepidermal junction.4 Although our case was negative for IgM, there was a similar weak nonspecific distribution of IgG. Kokturk et al5 described a case of bullous EAI in a man with repeated exposure to a space heater. The lesions showed subepidermal separation of the epidermis; increased elastic fibers; dilated dermal capillaries; melanophages in the upper dermis; and a mild, superficial, perivascular-lymphocytic infiltrate. Direct immunofluorescence showed no immune deposits.5 Several earlier cases of bullae associated with EAI have been reported in the literature but were thought to be bullous lichen planus superimposed on EAI.6 Our case, which exhibited similar historical, physical, and histopathologic findings, strengthens the argument for a defined bullous variant of EAI.

To the Editor:

Erythema ab igne (EAI) is a reticular erythematous hyperpigmentation of skin repeatedly exposed to moderate heat.1 It usually is asymptomatic, though some patients report itching or burning at the site.2 Historically caused by exposure to coal stoves or open fires, EAI has become increasingly common among individuals using space heaters, heating pads, or laptop computers near bare skin.2,3 Although EAI itself is benign and usually resolves with the removal of the exposure, it remains of clinical importance because of its association with underlying chronic disease, as chronic pain often is managed with frequent heating pad or hot water bottle use.2 Additionally, accurate diagnosis is important given the future risk for malignancy, as chronic changes of EAI have been reported to lead to squamous cell carcinoma or rarely Merkel cell carcinoma.2 Erythema ab igne is not traditionally associated with the formation of bullae; however, we present a case of bullous EAI that we believe highlights the importance of including this condition in the differential diagnosis of bullous disorders.

A 55-year-old man was admitted for presumed cellulitis of the bilateral legs. The patient had developed hyperpigmented discoloration of the medial surface of both legs with subsequent formation of tense bullae over the last 2 months. The dermatology department was consulted, as there was concern for bullous pemphigoid. The patient’s medical history was notable for hypertension, hyperlipidemia, diet-controlled type 2 diabetes mellitus, and hepatitis C virus with cirrhosis. The patient denied pruritus, pain, or known exposure of the legs to potential irritants prior to developing the lesions; however, with additional questioning he did report frequently sitting in front of a space heater with bare legs. Physical examination revealed multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (Figure 1). Many of the bullae were unroofed with full-thickness ulceration. Biopsies were taken for hematoxylin and eosin staining (Figure 2) and direct immunofluorescence.

Figure 1. Bullous erythema ab igne. Bilateral legs (A) with multiple areas of reticulated erythematous hyperpigmentation with several overlying bullae (B).

Basic hematologic and metabolic laboratory test results as well as blood cultures were negative. Wound culture was positive for methicillin-resistant Staphylococcus aureus. Histologic examination showed interface dermatitis with subepidermal vesicle (Figure 2). Scattered necrotic keratinocytes were present in the adjacent epidermis, and focal subtle vacuolar alteration of the dermoepidermal junction was seen (Figure 3). Sparse perivascular mononuclear cells and scattered melanophages were present in the dermis. Direct immunofluorescence showed no diagnostic immunopathologic abnormality. Focal weak nonspecific vascular positivity for IgG and C3 was seen, but IgA and IgM were negative. Although not specific, these changes were compatible with EAI in the clinical context provided. The diagnosis of bullous EAI with superimposed staphylococcal infection was made.

Figure 2. Bullous erythema ab igne. Interface dermatitis with subepidermal vesicle (H&E, original magnification ×100).

Figure 3. Bullous erythema ab igne. Scattered necrotic keratinocytesin the adjacent epidermis and focal subtle vacuolar alteration of the dermoepidermal junction (H&E, original magnification ×400).

Although rare, there have been reports of a bullous variant of EAI. Flanagan et al4 described 3 cases of bullous EAI with histopathology similar to our case. All 3 biopsies showed subepidermal separation with a mild perivascular dermal lymphocytic infiltrate. Direct immunofluorescence was negative in 2 cases but showed nonspecific weak patchy deposition of IgM along the dermoepidermal junction.4 Although our case was negative for IgM, there was a similar weak nonspecific distribution of IgG. Kokturk et al5 described a case of bullous EAI in a man with repeated exposure to a space heater. The lesions showed subepidermal separation of the epidermis; increased elastic fibers; dilated dermal capillaries; melanophages in the upper dermis; and a mild, superficial, perivascular-lymphocytic infiltrate. Direct immunofluorescence showed no immune deposits.5 Several earlier cases of bullae associated with EAI have been reported in the literature but were thought to be bullous lichen planus superimposed on EAI.6 Our case, which exhibited similar historical, physical, and histopathologic findings, strengthens the argument for a defined bullous variant of EAI.

References
  1. Baruchin AM. Erythema ab igne—a neglected entity? Burns. 1994;20:460-462.
  2. Arnold AW, Itin PH. Laptop computer−induced erythema ab igne in a child and review of the literature [published online October 4, 2010]. Pediatrics. 2010;126:E1227-E1230.
  3. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162:77-78.
  4. Flanagan N, Watson R, Sweeney E, et al. Bullous erythema ab igne. Br J Dermatol. 1996;134:1159-1160.
  5. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  6. Horio T, Imamura S. Bullous lichen planus developed on erythema ab igne. J Dermatol. 1986;13:203-207.
References
  1. Baruchin AM. Erythema ab igne—a neglected entity? Burns. 1994;20:460-462.
  2. Arnold AW, Itin PH. Laptop computer−induced erythema ab igne in a child and review of the literature [published online October 4, 2010]. Pediatrics. 2010;126:E1227-E1230.
  3. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162:77-78.
  4. Flanagan N, Watson R, Sweeney E, et al. Bullous erythema ab igne. Br J Dermatol. 1996;134:1159-1160.
  5. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  6. Horio T, Imamura S. Bullous lichen planus developed on erythema ab igne. J Dermatol. 1986;13:203-207.
Issue
Cutis - 100(2)
Issue
Cutis - 100(2)
Page Number
E9-E10
Page Number
E9-E10
Publications
Publications
Topics
Article Type
Display Headline
Space Heater–Induced Bullous Erythema Ab Igne
Display Headline
Space Heater–Induced Bullous Erythema Ab Igne
Sections
Inside the Article

Practice Points

  • Consider erythema ab igne (EAI) as a potential differential diagnosis in bullous eruptions.
  • Space heaters, heating pads, and even laptop computers should be considered as potential causes of EAI.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media

cureCADASIL Announces Publication of Study Results

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
cureCADASIL Announces Publication of Study Results

The cureCADASIL Association has announced the publication of a study by Dr. Arboleda-Velasquez in the Journal of Experimental Medicine. CADASIL is a disorder of the small blood vessels that causes subcortical transient ischemic attacks or strokes and progresses to early vascular dementia.

Publications
Topics
Sections

The cureCADASIL Association has announced the publication of a study by Dr. Arboleda-Velasquez in the Journal of Experimental Medicine. CADASIL is a disorder of the small blood vessels that causes subcortical transient ischemic attacks or strokes and progresses to early vascular dementia.

The cureCADASIL Association has announced the publication of a study by Dr. Arboleda-Velasquez in the Journal of Experimental Medicine. CADASIL is a disorder of the small blood vessels that causes subcortical transient ischemic attacks or strokes and progresses to early vascular dementia.

Publications
Publications
Topics
Article Type
Display Headline
cureCADASIL Announces Publication of Study Results
Display Headline
cureCADASIL Announces Publication of Study Results
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Alpha-1 Foundation Announces Funding Opportunities

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
Alpha-1 Foundation Announces Funding Opportunities

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

Publications
Topics
Sections

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

Publications
Publications
Topics
Article Type
Display Headline
Alpha-1 Foundation Announces Funding Opportunities
Display Headline
Alpha-1 Foundation Announces Funding Opportunities
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

NORD Welcomes All Things Kabuki as New Member

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
NORD Welcomes All Things Kabuki as New Member

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

Publications
Topics
Sections

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

Publications
Publications
Topics
Article Type
Display Headline
NORD Welcomes All Things Kabuki as New Member
Display Headline
NORD Welcomes All Things Kabuki as New Member
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

Publications
Topics
Sections

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

Publications
Publications
Topics
Article Type
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

FDA Launches Expanded Access Navigator

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
FDA Launches Expanded Access Navigator

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Publications
Topics
Sections

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Publications
Publications
Topics
Article Type
Display Headline
FDA Launches Expanded Access Navigator
Display Headline
FDA Launches Expanded Access Navigator
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Examining the Role of Caregivers at NINR Caregiving Summit

Article Type
Changed
Fri, 01/18/2019 - 08:48

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Publications
Topics
Sections

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

FDA Commissioner to Present Keynote Address at NORD Summit

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Publications
Topics
Sections

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Publications
Publications
Topics
Article Type
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products

Article Type
Changed
Fri, 01/18/2019 - 08:48
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Publications
Topics
Sections

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Publications
Publications
Topics
Article Type
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Paraneoplastic Acrokeratosis Bazex Syndrome: Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin

Article Type
Changed
Thu, 01/10/2019 - 13:44
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
Article PDF
Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Issue
Cutis - 100(2)
Publications
Topics
Page Number
E3-E5
Sections
Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Article PDF
Article PDF

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
Issue
Cutis - 100(2)
Issue
Cutis - 100(2)
Page Number
E3-E5
Page Number
E3-E5
Publications
Publications
Topics
Article Type
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin
Sections
Inside the Article

Practice Points

  • Paraneoplastic acrokeratosis may mimic palmo-plantar acrokeratosis in both clinical presentation and treatment.
  • Uncommon associations of paraneoplastic acrokeratosis with different types of lymphoma have been described.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media